Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06446063
Status:
RECRUITING
Last Update Posted:
2024-06-06
First Post:
2024-05-07
Brief Title:
Efficacy Tolerance of Cosmetic Product RV5098A on Face Pigmentation Maintenance in Adult Vitiligo Patients
Sponsor:
Pierre Fabre Dermo Cosmetique
Organization:
Pierre Fabre Dermo Cosmetique
Study Overview
Official Title:
Efficacy and Tolerance of the Cosmetic Care Product RV5098A on the Maintenance of Pigmentation on Face in Adult Patients With Vitiligo
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Vitiligo is an autoimmune depigmentation disorder affecting 05 to 1 of the population worldwide Vitiligo lesions are characterized by a progressive loss of pigmentation caused by the disappearance of functioning melanocytes in the epidermis mainly resulting from the activation of immune cells in a genetically predisposed patient
Despite major advances in the understanding of the mechanisms of the disease the treatment remains challenging Different treatment strategies could lead to cosmetically acceptable repigmentation 75 particularly on face and neck However after repigmentation the risk of relapse is estimated at nearly 40 during the first year after stopping treatment
To date long-term management remains a challenge With their topical product RV5098A adapted for patients with vitiligo Pierre Fabre Laboratories hypothesize that it could be effective in maintaining pigmentation of previously repigmented lesions in adults with facial vitiligo
Despite major advances in the understanding of the mechanisms of the disease the treatment remains challenging Different treatment strategies could lead to cosmetically acceptable repigmentation 75 particularly on face and neck However after repigmentation the risk of relapse is estimated at nearly 40 during the first year after stopping treatment
To date long-term management remains a challenge With their topical product RV5098A adapted for patients with vitiligo Pierre Fabre Laboratories hypothesize that it could be effective in maintaining pigmentation of previously repigmented lesions in adults with facial vitiligo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None